Global Structural Heart Device Market Size By Type (Aorta, Mitral), By Application (Repair, Annuloplasty), By Region, And Segment Forecasts, 2023 to 2032

The Global Structural Heart Device Market was valued at USD 14.7 billion in 2023 and is projected to reach USD 31.4 billion by 2031, growing at a CAGR of 9.8% during the forecast period from 2023 to 2031. This growth is driven by the rising incidence of congenital heart defects, valvular heart diseases, and cardiomyopathies, along with technological advancements in minimally invasive devices. Structural heart devices such as transcatheter aortic valve replacement (TAVR), occluders, annuloplasty rings, and heart valves are seeing increasing adoption due to the growing elderly population and rising preference for catheter-based procedures over traditional surgeries.

Drivers:

1. Rising Prevalence of Structural Heart Diseases:

Increasing rates of congenital and acquired structural heart conditions, such as aortic stenosis and atrial septal defects, are major factors fueling demand for corrective devices.

2. Technological Advancements in Device Design:

Innovations such as next-generation TAVR systems, advanced imaging-guided delivery platforms, and biodegradable occluders are enhancing procedural outcomes and patient recovery times.

3. Surge in Geriatric Population:

Older individuals are more susceptible to structural heart disorders. The global aging population directly contributes to the rising need for valve repair and replacement procedures.

Restraints:

1. High Cost of Procedures and Devices:

Structural heart interventions, particularly those involving TAVR and TMVR (transcatheter mitral valve replacement), are expensive, limiting access in low- and middle-income countries.

2. Stringent Regulatory Approval Processes:

The structural heart device market faces lengthy regulatory pathways and stringent clinical trial requirements, which can delay product launches and market expansion.

Opportunity:

1. Expanding Applications in Emerging Economies:

With healthcare infrastructure improving across Asia-Pacific and Latin America, the demand for structural heart solutions is expected to grow significantly in these underserved regions.

2. Increasing Adoption of Minimally Invasive Surgeries:

The shift from open-heart surgery to catheter-based interventions opens new avenues for growth, driven by shorter hospital stays and quicker patient recovery.

Market by System Type Insights:

Based on system type, the Transcatheter Aortic Valve Replacement (TAVR) segment led the market in 2023 due to its effectiveness in treating high-risk patients with aortic stenosis. The Transcatheter Mitral Valve Repair (TMVR) segment is expected to witness the fastest growth during the forecast period, fueled by ongoing clinical trials and growing physician awareness.

Market by End-use Insights:

The Hospitals segment accounted for the largest share of the market in 2023, attributed to the availability of specialized cardiovascular units and skilled professionals. However, Ambulatory Surgical Centers (ASCs) are poised for rapid growth, especially in North America and Europe, owing to lower procedural costs and reduced hospital stays.

Market by Regional Insights:

North America dominated the market in 2023, supported by high adoption of advanced devices, well-established reimbursement frameworks, and strong presence of key manufacturers. Asia-Pacific is projected to grow at the highest CAGR during the forecast period, propelled by increasing healthcare investments, rising awareness, and an expanding patient pool in countries like China and India.

Competitive Scenario:

Key players in the Global Structural Heart Device Market include Edwards Lifesciences Corporation, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, and CryoLife, Inc. These companies are focused on launching new-generation valve systems, expanding indications for use, and forming strategic partnerships to enhance their market footprint.

Key Developments:

In 2023, Edwards Lifesciences gained FDA approval for its next-gen TAVR system designed to improve positioning accuracy and minimize paravalvular leak.

Abbott announced CE mark approval in 2024 for its innovative transcatheter tricuspid valve repair system targeting previously untreated patients.

In 2025, Medtronic expanded its production facility in Ireland to meet the increasing global demand for structural heart solutions.

Scope of Work – Global Structural Heart Device Market

Report Metric Details

Market Size (2023) USD 14.7 billion

Projected Market Size (2031) USD 31.4 billion

CAGR (2023–2031) 9.8%

Market Segments By System Type (TAVR, TMVR, Occluders, Others); By End-use (Hospitals, ASCs, Cardiac Centers); By Region

Growth Drivers Increasing prevalence of structural heart diseases, Technological advancements, Aging population

Opportunities Emerging market expansion, Rise in minimally invasive cardiac procedures

FAQs:

1) What is the current market size of the Global Structural Heart Device Market?

The market was valued at USD 14.7 billion in 2023.

2) What is the major growth driver of the Global Structural Heart Device Market?

The increasing prevalence of structural heart diseases and aging population are the major growth drivers.

3) Which is the largest region during the forecast period in the Global Structural Heart Device Market?

North America held the largest share in 2023, while Asia-Pacific is expected to grow at the fastest pace.

4) Which segment accounted for the largest market share in the Global Structural Heart Device Market?

The TAVR segment held the largest market share in 2023.

5) Who are the key market players in the Global Structural Heart Device Market?

Major players include Edwards Lifesciences, Medtronic, Abbott Laboratories, Boston Scientific, and LivaNova.

Would you like a visual summary or infographic to accompany this description?